Medicus Reports Phase 2 Results for SkinJect Basal Cell Carcinoma Study
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) reported additional data from its Phase 2 SKNJCT-003 clinical study evaluating the SkinJect microneedle delivery system for the treatment of basal cell …
Medicus Reports Phase 2 Results for SkinJect Basal Cell Carcinoma Study Read More